Page 347 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 347
P1334 A MULTICENTRE, RANDOMISED, OPEN-LABEL STUDY ePOSTERS
COMPARING THE EFFICACY AND SAFETY OF TWO DOSES
P1335 OF DOXORUBICIN TRANSDRUG™ TO BEST STANDARD OF
YI P1336 CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR
YI P1337 CARCINOMA (HCC) AFTER SORAFENIB. THE RELIVE
STUDY
Philippe Merle*, Gilles Pelletier, François Habersetzer,
Giovanni Luca Frassineti, George-Philippe Pageaux, Ivan Borbath,
René Gérolami, Gloria Sánchez Antolín, Jean-Pierre Bronowicki,
Zsolt Horváth,Yann Touchefeu, Andreas Maieron, Henning Wege,
Valériy Breder, Nashat Gabrail, Bérangère Vasseur, Pierre Attali,
Jean-Frédéric Blanc, France
A RANDOMIZED, CONTROLLED PHASE III TRIAL OF
SORAFENIB WITH OR WITHOUT CONVENTIONAL
TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS
WITH ADVANCED HEPATOCELLULAR CARCINOMA (STAH)
Joong-Won Park*,Yoon Jun Kim, Do Young Kim, Si Hyun Bae,
Jong Eun Yeon, Sang Young Han, Jae Seok Hwang,Youn-Jae Lee,
Jae Youn Cheong, Oh Sang Kwon, Hwi Young Kim, Han Chu Lee,
Jeong Heo, Bo Hyun Kim, Seung Woon Paik, South Korea
TREATMENT OF TYPE 1 HEPATORENAL SYNDROME WITH
TERLIPRESSIN INFUSION ADJUSTED ACCORDING TO
HEMODYNAMIC RESPONSE. THE AMELIORATE STUDY
Patricia Huelin*, Ezequiel Rodriguez, Maria Poca, Marta Martin-Llahi,
Chiara Elia, Rebeca Moreira, Cristina Solè, Isabel CireraJordi Sanchez,
Victor Vargas, German Soriano, Vicente Arroyo, Elsa Sola, Pere Gines,
Spain
RANDOMIZED TRIAL WITH RIFAXIMIN IN LIVER
CIRRHOSIS. EFFECTS ON THE HAEMODYNAMIC AND
INFLAMMATORY STATE
Nina Kimer*, Julie S. Pedersen, Søren Møller, Aleksander Krag,
Flemming Bendtsen, Denmark
Vienna, Austria • April 22–26, 2015 347
COMPARING THE EFFICACY AND SAFETY OF TWO DOSES
P1335 OF DOXORUBICIN TRANSDRUG™ TO BEST STANDARD OF
YI P1336 CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR
YI P1337 CARCINOMA (HCC) AFTER SORAFENIB. THE RELIVE
STUDY
Philippe Merle*, Gilles Pelletier, François Habersetzer,
Giovanni Luca Frassineti, George-Philippe Pageaux, Ivan Borbath,
René Gérolami, Gloria Sánchez Antolín, Jean-Pierre Bronowicki,
Zsolt Horváth,Yann Touchefeu, Andreas Maieron, Henning Wege,
Valériy Breder, Nashat Gabrail, Bérangère Vasseur, Pierre Attali,
Jean-Frédéric Blanc, France
A RANDOMIZED, CONTROLLED PHASE III TRIAL OF
SORAFENIB WITH OR WITHOUT CONVENTIONAL
TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS
WITH ADVANCED HEPATOCELLULAR CARCINOMA (STAH)
Joong-Won Park*,Yoon Jun Kim, Do Young Kim, Si Hyun Bae,
Jong Eun Yeon, Sang Young Han, Jae Seok Hwang,Youn-Jae Lee,
Jae Youn Cheong, Oh Sang Kwon, Hwi Young Kim, Han Chu Lee,
Jeong Heo, Bo Hyun Kim, Seung Woon Paik, South Korea
TREATMENT OF TYPE 1 HEPATORENAL SYNDROME WITH
TERLIPRESSIN INFUSION ADJUSTED ACCORDING TO
HEMODYNAMIC RESPONSE. THE AMELIORATE STUDY
Patricia Huelin*, Ezequiel Rodriguez, Maria Poca, Marta Martin-Llahi,
Chiara Elia, Rebeca Moreira, Cristina Solè, Isabel CireraJordi Sanchez,
Victor Vargas, German Soriano, Vicente Arroyo, Elsa Sola, Pere Gines,
Spain
RANDOMIZED TRIAL WITH RIFAXIMIN IN LIVER
CIRRHOSIS. EFFECTS ON THE HAEMODYNAMIC AND
INFLAMMATORY STATE
Nina Kimer*, Julie S. Pedersen, Søren Møller, Aleksander Krag,
Flemming Bendtsen, Denmark
Vienna, Austria • April 22–26, 2015 347
